Arvinas (ARVN) Competitors $7.28 +0.18 (+2.46%) As of 02:59 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ARVN vs. MESO, ADPT, ANIP, CGON, VCEL, SRPT, BEAM, ARQT, TWST, and SPRYShould you be buying Arvinas stock or one of its competitors? The main competitors of Arvinas include Mesoblast (MESO), Adaptive Biotechnologies (ADPT), ANI Pharmaceuticals (ANIP), CG Oncology (CGON), Vericel (VCEL), Sarepta Therapeutics (SRPT), Beam Therapeutics (BEAM), Arcutis Biotherapeutics (ARQT), Twist Bioscience (TWST), and ARS Pharmaceuticals (SPRY). These companies are all part of the "pharmaceutical products" industry. Arvinas vs. Its Competitors Mesoblast Adaptive Biotechnologies ANI Pharmaceuticals CG Oncology Vericel Sarepta Therapeutics Beam Therapeutics Arcutis Biotherapeutics Twist Bioscience ARS Pharmaceuticals Mesoblast (NASDAQ:MESO) and Arvinas (NASDAQ:ARVN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability. Do insiders & institutionals have more ownership in MESO or ARVN? 1.4% of Mesoblast shares are held by institutional investors. Comparatively, 95.2% of Arvinas shares are held by institutional investors. 18.8% of Mesoblast shares are held by company insiders. Comparatively, 4.7% of Arvinas shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Is MESO or ARVN more profitable? Mesoblast has a net margin of 0.00% compared to Arvinas' net margin of -19.47%. Mesoblast's return on equity of 0.00% beat Arvinas' return on equity.Company Net Margins Return on Equity Return on Assets MesoblastN/A N/A N/A Arvinas -19.47%-12.01%-6.97% Which has higher valuation & earnings, MESO or ARVN? Mesoblast has higher earnings, but lower revenue than Arvinas. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMesoblast$5.90M326.12-$87.96MN/AN/AArvinas$263.40M2.02-$198.90M-$1.01-7.19 Does the media refer more to MESO or ARVN? In the previous week, Mesoblast had 4 more articles in the media than Arvinas. MarketBeat recorded 4 mentions for Mesoblast and 0 mentions for Arvinas. Mesoblast's average media sentiment score of 0.59 beat Arvinas' score of -0.06 indicating that Mesoblast is being referred to more favorably in the media. Company Overall Sentiment Mesoblast Positive Arvinas Neutral Which has more volatility and risk, MESO or ARVN? Mesoblast has a beta of 2.4, suggesting that its stock price is 140% more volatile than the S&P 500. Comparatively, Arvinas has a beta of 2.22, suggesting that its stock price is 122% more volatile than the S&P 500. Do analysts rate MESO or ARVN? Mesoblast presently has a consensus price target of $18.00, suggesting a potential upside of 19.74%. Arvinas has a consensus price target of $19.76, suggesting a potential upside of 172.33%. Given Arvinas' higher possible upside, analysts plainly believe Arvinas is more favorable than Mesoblast.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mesoblast 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.20Arvinas 0 Sell rating(s) 10 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 2.55 SummaryMesoblast beats Arvinas on 11 of the 15 factors compared between the two stocks. Get Arvinas News Delivered to You Automatically Sign up to receive the latest news and ratings for ARVN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ARVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARVN vs. The Competition Export to ExcelMetricArvinasMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$533.40M$3.12B$5.76B$9.55BDividend YieldN/A2.23%4.53%4.07%P/E Ratio-7.1920.4630.4325.11Price / Sales2.02237.31392.2187.48Price / CashN/A42.3737.0358.50Price / Book0.877.959.016.20Net Income-$198.90M-$54.72M$3.26B$265.38M7 Day Performance2.50%1.56%1.00%-1.25%1 Month Performance-3.50%5.71%4.19%-0.81%1 Year Performance-71.12%9.01%28.39%18.83% Arvinas Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARVNArvinas3.7488 of 5 stars$7.28+2.5%$19.76+171.7%-71.6%$533.69M$263.40M-7.20420MESOMesoblast2.0737 of 5 stars$14.70-2.2%$18.00+22.4%+136.0%$1.88B$5.90M0.0080News CoverageUpcoming EarningsADPTAdaptive Biotechnologies2.607 of 5 stars$12.15-0.4%$12.38+1.9%+168.0%$1.85B$178.96M-14.82790Analyst RevisionANIPANI Pharmaceuticals3.0878 of 5 stars$84.88+4.2%$84.75-0.2%+48.1%$1.84B$674.07M-110.23600Trending NewsInsider TradeHigh Trading VolumeCGONCG Oncology1.3718 of 5 stars$23.94-3.7%$55.30+131.0%-28.0%$1.82B$1.14M-13.5361News CoverageAnalyst ForecastVCELVericel2.5135 of 5 stars$35.43-2.2%$60.33+70.3%-25.0%$1.79B$249.12M295.27300Positive NewsSRPTSarepta Therapeutics4.5955 of 5 stars$17.94-1.6%$44.17+146.2%-85.4%$1.75B$2.48B-20.621,372Trending NewsAnalyst ForecastShort Interest ↑Gap DownBEAMBeam Therapeutics2.2156 of 5 stars$17.17-2.6%$48.45+182.2%-34.5%$1.74B$63.52M-3.82510ARQTArcutis Biotherapeutics2.5857 of 5 stars$14.19-3.9%$19.80+39.5%+87.5%$1.70B$196.54M-18.92150Positive NewsTWSTTwist Bioscience4.1334 of 5 stars$27.63+7.8%$49.40+78.8%-38.4%$1.67B$312.97M-19.06990High Trading VolumeSPRYARS Pharmaceuticals2.5043 of 5 stars$16.38-6.4%$31.00+89.3%-1.9%$1.61B$97.12M-102.3790Analyst Revision Related Companies and Tools Related Companies MESO Competitors ADPT Competitors ANIP Competitors CGON Competitors VCEL Competitors SRPT Competitors BEAM Competitors ARQT Competitors TWST Competitors SPRY Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ARVN) was last updated on 8/21/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arvinas, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arvinas With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access